Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Mark M Pomerantz, M.D.

TitleAssistant Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Medicine, Dana Bldg Rm 1230
Boston MA 02215
Phone617/632-4524
Fax617/632-2165

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease. Cancer. 2013 Aug 15; 119(16):2990-8.
    View in: PubMed
  2. Pomerantz M, Freedman ML. Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med. 2013 Apr 24; 5(182):182ed6.
    View in: PubMed
  3. Choueiri TK, Pomerantz MM, Signoretti S. Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013 Feb; 14(2):105-7.
    View in: PubMed
  4. Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
  5. Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):483-90.
    View in: PubMed
  6. Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
    View in: PubMed
  7. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T. The role of genetic markers in the management of prostate cancer. Eur Urol. 2012 Oct; 62(4):577-87.
    View in: PubMed
  8. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GS, Kantoff PW. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 1; 72(10):1093-103.
    View in: PubMed
  9. Pomerantz MM, Freedman ML. The genetics of cancer risk. Cancer J. 2011 Nov-Dec; 17(6):416-22.
    View in: PubMed
  10. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50.
    View in: PubMed
  11. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
    View in: PubMed
  12. Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28.
    View in: PubMed
  13. Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52.
    View in: PubMed
  14. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov; 6(11):e1001204.
    View in: PubMed
  15. Pomerantz MM, Freedman ML. Genetics of prostate cancer risk. Mt Sinai J Med. 2010 Nov-Dec; 77(6):643-54.
    View in: PubMed
  16. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 1; 16(21):5244-51.
    View in: PubMed
  17. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8.
    View in: PubMed
  18. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A. 2010 May 25; 107(21):9742-6.
    View in: PubMed
  19. Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, Sestrehenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):1-8.
    View in: PubMed
  20. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597.
    View in: PubMed
  21. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet. 2009 Aug; 41(8):882-4.
    View in: PubMed
  22. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 1; 69(13):5568-74.
    View in: PubMed
  23. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 1; 15(9):3223-30.
    View in: PubMed
  24. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 1; 115(5):981-7.
    View in: PubMed
  25. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
    View in: PubMed
  26. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
    View in: PubMed
  27. Pomerantz MM, Freedman ML, Kantoff PW. Genetic determinants of prostate cancer risk. BJU Int. 2007 Aug; 100(2):241-3.
    View in: PubMed
  28. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
    View in: PubMed
  29. Amy Kallmerten, Brittany Rowland, Mark Pomerantz, William Oh, and James Glick. . Quantitation of estrogens in male plasma using liquid chromatography with an electrochemical detector. American Chemical Society. 2007.
  30. Mark Pomerantz, Nora Y. Osman and William K. Oh. . Diagnosis and treatment of low-grade prostate cancer. Hospital Physician. 2007.
  31. Robert Ross, William Oh, Wang Xie, Mark Pomerantz, Mari Nakabayashi, Philip Kantoff, Matthew Freedman. . Genetic polymorphisms in genes responsible for androgen metabolism are associated with time to prostate specific antigen progression (PSA-TTP) on primary androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSCaP). Proc American Society of Clinical Oncology Prostate. 2007.
  32. Pomerantz M, Kantoff P. Advances in the treatment of prostate cancer. Annu Rev Med. 2007; 58:205-20.
    View in: PubMed
  33. Mark Pomerantz, Judith Manola, Mary-Ellen Taplin, Glenn Bubley, Clair Beard, Margaret Inman, Jennifer Lowell, Philip Kantoff, William K. Oh. . Phase II study of low dose and high dose premarin in androgen independent prostate cancer. Journal of Urology. 2007.
  34. Mark Pomerantz and Philip Kantoff. Genetics and inherited prostate cancer risk. Contemporary Urology. 2006; 18-25.
  35. Mark Pomerantz, Judith Manola, Mary-Ellen Taplin, Glenn Bubley, Clair Beard, Margaret Inman, Jennifer Lowell, Philip Kantoff, William K. Oh. . Phase II study of low dose and high dose premarin in androgen independent prostate cancer. Proc American Society of Clinical Oncology. 2006.
  36. Varant Kupelian, Mark Pomerantz, Thomas Travison, Andre Araujo, Philip Kantoff, John McKinlay. . Is change in testosterone levels associated with an increase in prostate cancer risk? Results from the Massachusetts Male Aging Study (MMAS). Society for Epidemiologic Research. 2006.
  37. Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg. 2001 Mar; 121(3):448-53.
    View in: PubMed
  38. POMERANTZ M, KISER WS. LYMPHANGIOGRAPHY: ITS USE IN THE DIAGNOSIS AND TREATMENT OF UROLOGIC DISORDERS. J Urol. 1964 Feb; 91:190-4.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Pomerantz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_